They are doing a review early on and if the data shows the 700mg is more effective then they'll scrap the 350mg arm. It's not like they're not giving 700mg a chance. If the drug works as expected then this study should hopefully drive a nail into the lower dosage regimens.

Per newsletter:

Quote:

---

After a preliminary safety review by the Data and Safety Monitoring Board (“DSMB”), subsequent patients will be randomized to 350 or 700 mg of weekly leronlimab along with the same background regimen. The DSMB will perform a second safety review after the first 20 patients have completed at least 1 cycle of therapy and can then recommend restricting further enrollment to a single dose level, if deemed appropriate.

---